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ABSTRACT
ObjeCtive
To assess whether use of specific selective serotonin 
reuptake inhibitors (SSRIs) or venlafaxine in early 
pregnancy is associated with an increased risk of birth 
defects, with emphasis on cardiovascular birth defects 
even when accounting for lifestyle or other familial 
confounding.
Design
Multicountry population based cohort study, including 
sibling controlled design.
setting
Nordic population (Denmark, Finland, Iceland, Norway, 
and Sweden) identified from nationwide health 
registers at different periods in 1996-2010.
POPulatiOn
The full study cohort included women giving birth to 
2.3 million live singletons. The sibling cohort included 
2288 singleton live births. The sibling controlled 
analyses included sibling pairs who were discordant 
for exposure to SSRIs or venlafaxine and birth defects.
Main OutCOMe Measure
Prevalence of birth defects, including subtypes of 
cardiac defects. Odds ratio of birth defects from 
logistic and conditional logistic regression.
results
Among 36 772 infants exposed to any SSRI in early 
pregnancy, 3.7% (n=1357) had a birth defect 
compared with 3.1% of 2 266 875 unexposed infants, 
yielding a covariate adjusted odds ratio of 1.13 (95% 
confidence interval 1.06 to 1.20). In the sibling 
controlled analysis the adjusted odds ratio decreased 
to 1.06 (0.91 to 1.24). The odds ratios for any cardiac 
birth defect with use of any SSRI or venlafaxine were 
1.15 (95% confidence interval 1.05 to 1.26) in the 
covariate adjusted analysis and 0.92 (0.72 to 1.17) in 
the sibling controlled analysis. For atrial and 
ventricular septal defects the covariate adjusted odds 
ratio was 1.17 (1.05 to 1.31). Exposure to any SSRI or 
venlafaxine increased the prevalence of right 
ventricular outflow tract obstruction defects, with a 
covariate adjusted odds ratio of 1.48 (1.15 to 1.89). In 
the sibling controlled analysis the adjusted odds ratio 
decreased to 0.56 (0.21 to 1.49) for any exposure to 
SSRIs or venlafaxine and right ventricular outflow tract 
obstruction defects.
COnClusiOns
In this large Nordic study no substantial increase was 
found in prevalence of overall cardiac birth defects 
among infants exposed to SSRIs or venlafaxine in 
utero. Although the prevalence of septal defects and 
right ventricular outflow tract defects was higher in 
exposed infants, the lack of an association in the 
sibling controlled analyses points against a 
teratogenic effect of these drugs.
Introduction
Depression is common in pregnancy.1  Selective sero-
tonin reuptake inhibitors (SSRIs) are the most fre-
quently used antidepressants in pregnant women, with 
as many as 3% of such women in Europe and 4-10% in 
North America receiving these drugs.2 3-6
The results of previous studies assessing the risk of 
birth defects after use of SSRIs in pregnancy have been 
conflicting.7  Most consistently reported were cardiovas-
cular birth defects.8-15  One study16  found an increased 
risk of cardiovascular defects with combined use of 
SSRIs or venlafaxine and benzodiazepines. Increased 
risks of anal atresia,7  hypospadias,7 14  clubfoot,7  limb 
reduction defects,7  craniosynostosis,8  omphalocele,7 8 
gastroschisis,8 and cystic kidneys17 have also been 
reported with use of SSRIs in early pregnancy, but less 
consistently. A few studies reported no increased risk of 
congenital birth defects associated with use of SSRIs in 
pregnancy.13 18 19
Venlafaxine is a serotonin-norepinephrine reuptake 
inhibitor used increasingly as an alternative to SSRIs.20 
Recently, a case-control study from the United States, 
based on 77 exposed cases and 14 exposed controls, 
reported that use of venlafaxine in early pregnancy was 
associated with several types of birth defects, with odds 
ratios ranging from 1.5 to 6.3.21
WhAT IS AlReAdy knoWn on ThIS TopIC
The teratogenicity of individual selective serotonin reuptake inhibitors (SSRIs) and 
venlafaxine remains controversial
Few studies have had sufficient power to study the direct effect of individual SSRIs 
on specific birth defects
WhAT ThIS STudy AddS
In this large population based cohort study including sibling controlled analyses, 
there was no substantial increase in prevalence of overall cardiac birth defects 
among infants exposed to SSRIs or venlafaxine in utero
Although the prevalence of right ventricular outflow tract defects was higher in 
exposed infants in the full cohort, no association was found in the sibling 
controlled analyses
The general absence of strong associations between birth defects and SSRIs and 
venlafaxine is reassuring
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Limitations of previous studies include uncertain 
information on drug use, recall bias from self reports, 
limited information on confounding factors, and low 
statistical power. Larger studies are necessary for more 
definitive conclusions about particular types of birth 
defects and associations with specific drugs, rather 
than classes of drugs.22
The Nordic countries, representing a total popula-
tion of about 26 million people, have similar nation-
wide registers of births and dispensed drugs, enabling 
large studies on the effects of rare drug exposures 
during pregnancy on birth defects.23 We performed a 
population based cohort study and a sibling con-
trolled analysis within five Nordic countries to assess 
predefined and previously reported associations 
between exposure to individual SSRIs or venlafaxine 
in the first trimester and the risk of specific birth 
defects, with emphasis on cardiovascular defects, 
adjusting for important covariates such as familial 
factors.
Methods
Data sources and study population
In this population based study we included women 
from Denmark, Finland, Iceland, Norway, and Sweden 
who gave birth to a live singleton infant between 1996 
and 2010. From nationwide health registers in each 
 Nordic country we obtained data on births, dispensed 
drugs, birth defects, and potential confounders. These 
registers include prospectively collected health infor-
mation on all inhabitants. A civil personal registration 
number is assigned to each resident at birth or immigra-
tion, enabling data linkage between the registers. 
Reporting to the registers is mandatory and regulated 
by national laws.
Each participating country contributed data for dif-
ferent periods corresponding to the availability of the 
prescription databases and other health registers. 
Accordingly we identified all live born singletons in 
Denmark 1997-2010, Finland 1996-2006, Iceland 2003-
07, Norway 2005-10, and Sweden 2006-10. We also iden-
tified siblings born to the same mother during these 
periods.
ascertainment of exposure
The Nordic prescription registers include data on dis-
pensed drugs, substance, brand name, and formula-
tion, together with date of dispensing.23  All drugs are 
classified according to the World Health Organiza-
tion’s Anatomical Therapeutic Chemical (ATC) classi-
fication.24 The following SSRIs were included in the 
analyses: fluoxetine (ATC code: N06AB03), citalo-
pram (N06AB04), paroxetine (N06AB05), sertraline 
(N06AB06), fluvoxamine (N06AB08), and escitalo-
pram (N06AB10), and in addition venlafaxine 
(N06AX16). We considered infants to have been 
exposed in utero if they were born to women who 
filled a prescription for an SSRI from 30 days before 
the first day of the last menstrual period until the end 
of the first trimester (defined as 97 days after the last 
menstrual period).
Major birth defects
From the medical birth, patient, and malformation 
 registers we retrieved data on maternal characteristics, 
the pregnancy and delivery, and major birth defects 
diagnosed within 365 days after birth. The patient regis-
ters record information on diagnoses and hospital vis-
its.25 26 During the study period, birth defects were 
recorded according to the international classification of 
diseases, 10th revision (ICD-10) in Denmark, Norway, 
Sweden, and Iceland, whereas ICD-9-CM codes (Atlanta 
modification for birth defects) were used in Finland (see 
appendix 1 on bmj.com for ICD codes).
We categorised cardiovascular birth defects into any 
cardiac defects; situs anomalies and looping defects; 
conotruncal and major aortic arch anomalies; ventral 
septal defect or atrial septal defect; atrioventricular 
septal defects; right ventricular outflow tract obstruc-
tion defects; and left ventricular outflow tract obstruc-
tion defects. In addition we assessed several specific 
birth defects based on results from previous stud-
ies8 9 15 17: anal atresia, hypospadias, clubfoot, limb 
reduction defects, craniosynostosis, omphalocele, gas-
troschisis, and cystic kidneys.
Potential confounding factors
We included the potential confounders of country of 
residence, maternal age at delivery, calendar year of 
delivery, birth order, maternal smoking during preg-
nancy, maternal diabetes, and concurrent drug use. The 
presence of maternal diabetes was defined as dispensed 
antidiabetic drugs (ATC code: A10) from 90 days before 
the first day of the last menstrual period to 97 days after 
the last menstrual period. Concurrent drugs considered 
as confounders included antiepileptics (N03), anxiolyt-
ics and hypnotics (N05B, N05C), and agents acting on 
the renin-angiotensin system (C09) dispensed from 30 
days before the first day of the last menstrual period 
until 97 days after the last menstrual period.
statistical analyses
We used logistic regression analysis to estimate odds 
ratios with 95% confidence intervals for all major and 
specific types of birth defects according to exposure 
 status, with adjustment for the included confounders. 
Owing to missing data on confounders, the number 
included in the adjusted analyses (n=2 145 050) was 
slightly lower than the number included in the crude 
analyses (n=2 303 647). In our primary analyses we 
assessed odds ratios for birth defects by exposure in 
early pregnancy to any SSRI and venlafaxine and to 
each specific SSRI or venlafaxine. In each instance the 
reference group comprised births of infants not exposed 
to any antidepressant (ATC code N06A) in utero. We 
present only the results from analyses with more than 
five births among exposed infants with the specific 
defect or defect group.
To adjust further for potential confounding from fam-
ily related factors, we conducted sibling controlled 
analyses by restricting the study population to women 
with at least two children in the dataset. Furthermore, 
we restricted the sibling analyses to families with 
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 siblings who were discordant for both exposure and 
outcome. Using conditional logistic regression we com-
pared the prevalence of birth defects overall, any car-
diac defects, and right ventricular outflow tract 
obstruction defects in infants exposed to any SSRI and 
venlafaxine with the prevalence in siblings not exposed 
to any antidepressants.
Predefined sensitivity analyses were performed for a 
shorter and a longer period of exposure—that is, dis-
pensed drugs from the first day of the last menstrual 
period until 97 days after the last menstrual period and 
from 90 days before the first day of the last menstrual 
period until 97 days after the last menstrual period, 
respectively. In addition we conducted secondary mul-
tivariable analyses stratified by use of anxiolytics and 
hypnotics. Finally, to account for confounding by sever-
ity of underlying psychiatric condition, we restricted 
the primary analyses to pregnant women without a pre-
vious hospital admission for a psychiatric condition.
All analyses were conducted using SAS software, ver-
sion 9.3 (SAS Institute, Cary, NC). The study was 
approved and performed according to ethical and legal 
requirements in each country.23
Patient involvement
There was no patient involvement in this study.
Results
The full study cohort included 2 303 647 singleton live 
births and the sibling cohort included 2288 singleton 
live births. In the full study cohort, 36 772 (1.6%) infants 
were exposed to a selective serotonin reuptake inhibitor 
(SSRI) or venlafaxine during the first trimester in 1996-
2010. The proportion of infants exposed to an SSRI or 
venlafaxine increased during the study period: from 0.6% 
in 1996-2000 to 1.5% in 2001-05 and 2.2% in 2006-10. 
Table 1  presents the characteristics of the full study 
cohort and the sibling cohort according to drug expo-
sure status. Citalopram and sertraline were the most 
commonly used SSRIs (table 2).
Among the 36 772 infants exposed to SSRIs or venla-
faxine during the first trimester, 1357 (3.7%) had a diag-
nosis of a major birth defect compared with 71 374 (3.2%) 
of the 2 266 875 unexposed infants (adjusted odds ratio 
1.13, 95% confidence interval 1.06 to 1.20, fig 1).
table 1 | Maternal and infant characteristics by exposure to selective serotonin reuptake inhibitors (ssris) or venlafaxine 
during first trimester*
Characteristics
no (%) in full cohort no (%) in sibling cohort
any ssri† (n=36 772) no ssri (n=2 266 875) any ssri† (n=980) no ssri (n=1308)
Maternal age at delivery (years):
 ≤24 6192 (16.8) 359 817 (15.9) 172 (17.6) 459 (35.1)
 25-34 22 209 (60.4) 1 490 718 (65.8) 643 (65.6) 732 (56.0)
 35-44 8304 (22.6) 413 939 (18.3) 165 (16.8) 117 (8.9)
 ≥45 67 (0.2) 2401 (0.1) 0 (0.0) 0 (0.0)
Birth order:
 1 16 439 (44.7) 962 629 (42.5) 217 (22.1) 481 (36.8)
 2-3 17 014 (46.3) 1 134 522 (50.0) 573 (58.5) 650 (49.7)
 ≥4 3113 (8.5) 151 386 (6.7) 186 (19.0) 166 (12.7)
 Missing 206 (0.6) 18 338 (0.8) 4 (0.4) 11 (0.8)
Maternal smoking in early pregnancy:
 No 24 611 (66.9) 1 810 213 (79.9) 656 (66.9) 887 (67.8)
 Yes 9371 (25.5) 317 437 (14.0) 288 (29.4) 373 (28.5)
 Missing 2790 (7.6) 139 225 (6.1) 36 (3.7) 48 (3.7)
Maternal diabetes‡:
 Yes 526 (1.4) 16 992 (0.7) 18 (1.8) 11 (0.8)
 No 36 246 (98.6) 2 249 883 (99.3) 962 (98.2) 1297 (99.2)
Exposed to other prescribed drugs§:
 Yes 5362 (14.6) 22 315 (1.0) 140 (14.3) 55 (4.2)
 No 31 410 (85.4) 2 244 560 (99.0) 840 (85.7) 1253 (95.8)
*The full study cohort included 2 303 647 singleton live births in five Nordic countries, 1996-2010, and the sibling cohort included 2288 singleton live births.
†Defined as dispensed SSRIs or venlafaxine to mothers at least once from 30 days before first day of last menstrual period to 97 days after last menstrual period.
‡Defined as dispensed drugs used for diabetes (ATC code A10) to mothers at least once from 90 days before first day of last menstrual period to 97 days 
after last menstrual period.
§Defined as the following drugs dispensed to mothers, antiepileptics (ATC code N03A), anxiolytics and hypnotics (N05B, N05C), angiotensin converting 
enzyme inhibitors (C09), at least once from 30 days before first day of last menstrual period to 97 days after last menstrual period.
table 2 | exposure to antidepressants during first trimester
substance (atC code) no (%) of infants
Any SSRI* (N06AB or N06AX16) 36 772 (1.60)
Fluoxetine (N06AB03) 6250 (0.27)
Citalopram (N06AB04) 11 193 (0.48)
Paroxetine (N06AB05) 2879 (0.12)
Sertraline (N06AB06) 7245 (0.31)
Fluvoxamine (N06AB08) 255 (0.01)
Escitalopram (N06AB10) 3950 (0.17)
Venlafaxine (N06AX16) 2763 (0.12)
Mixed† 2237 (0.10)
Other antidepressants‡ 7188 (0.31)
ATC=Anatomical Therapeutic Chemical classification.24
*Defined as dispensed selective serotonin-reuptake inhibitors (ATC 
N06AB) or venlafaxine (N06AX16) at least once from 30 days before first 
day of last menstrual period to 97 days after last menstrual period.
†Exposed to more than one of the listed drugs.
‡Exposed to any other antidepressant drug (ATC N06A) not listed. These 
are excluded from analyses.
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The prevalence of overall cardiac birth defects was 
1.5% among infants exposed to any SSRI or venlafaxine 
compared with 1.2% among infants in the unexposed 
group (1.15, 1.05 to 1.26). Apart from escitalopram, in utero 
exposure to each specific SSRI and to venlafaxine was 
associated with an increased prevalence of cardiac birth 
defects, with adjusted odds ratios between 1.13 and 1.34. 
Similarly, and except for escitalopram, atrial or ventricu-
lar septal defects were positively associated with mater-
nal use of each specific SSRI and with venlafaxine (fig 2).
The adjusted odds ratio for right ventricular outflow 
tract obstruction defects after exposure to any SSRI was 
1.48 (1.15 to 1.89), with estimates for specific SSRIs vary-
ing from 1.40 to 2.54 (fig 2). Use of paroxetine was asso-
ciated with an increased prevalence of conotruncal and 
major arch anomalies (2.27, 1.01 to 5.07), whereas asso-
ciations with other SSRIs were less clear.
The prevalence of clubfoot and omphalocele was 
increased after exposure to any SSRIs, but we found no 
increased prevalence of hypospadias, limb reduction, 
craniosynostosis, gastroschisis, or cystic kidneys (fig 3). 
Exposure to citalopram and sertraline were both associ-
ated with an increased prevalence of clubfoot, and ser-
traline also with anal atresia.
In the sibling controlled analyses we identified 895 
families with at least one exposed pregnancy and at 
least one birth with a malformation (tables 1 and 3). The 
adjusted odds ratios in the sibling controlled analyses 
were attenuated compared with estimates from the 
covariable adjusted analyses in the full cohort. The con-
fidence intervals were also wider in the sibling con-
trolled analyses.
The level of the odds ratios was not influenced by the 
order of exposure and outcome between the discordant 
siblings—that is, a first exposed sibling with a birth 
defect and an unexposed second sibling without a birth 
defect would yield odds ratios similar to a first unex-
posed sibling with no birth defects and a second 
exposed sibling with a birth defect.
In the predefined sensitivity analyses, using two dif-
ferent time windows for exposure, the effect estimates 
for birth defects associated with any SSRI were similar to 
those in the primary analyses. Stratification according 
to use of anxiolytics and hypnotics did not result in sub-
stantial variation of risk estimates between strata. The 
estimates were not substantially changed by restricting 
the primary analyses to women without previous 
admissions to hospital for psychiatric disorders (data 
not shown).
discussion
In this large multinational population based study 
including over 2.3 million births from the Nordic coun-
tries, exposure to selective serotonin reuptake inhibi-
tors (SSRIs) in utero was associated with a 13% 
increased prevalence of major birth defects and a 15% 
increased prevalence of cardiac defects in a covariate 
controlled analysis. However, we found no increased 
prevalence in the sibling controlled analyses, suggest-
ing that the small observed increased risk when includ-
ing mothers and their infants in the analyses could be 
explained by familial related factors or other lifestyle 
related factors not adjusted for. Similarly, each specific 
SSRI increased the prevalence of right ventricular out-
flow tract obstruction defects, with adjusted odds ratios 
ranging from 1.40 to 2.54, whereas no association was 
found in the sibling controlled analysis (0.71, 0.28 to 
1.78). No significant association was found between 
venlafaxine and birth defects.
Comparisons with other studies
Some of the births in our study have been included in 
previous national studies.11 12 15 27  The observed 
increased prevalence of overall major birth defects in 
association with exposure to SSRIs was lower than the 
21-30% increased risk reported in previous Danish stud-
ies,11 12 27  but extends the findings from a previous Finn-
ish study reporting no substantial increased risk of 
overall birth defects.15  In our data, SSRI use was associ-
ated with an increased prevalence of cardiovascular 
defects; mainly driven by a 30% increase after exposure 
to paroxetine or fluoxetine, which is an effect of similar 
size to that reported from databases in the United King-
dom18  and the United States.8  Previous studies report-
ing risks of birth defects in association with the 
combined use of SSRIs and benzodiazepines included 
Any SSRI
Fluoxetine
Citalopram 
Paroxetine 
Sertraline 
Fluvoxamine
Escitalopram 
Venlafaxine
1.13 (1.06 to 1.20)
1.25 (1.10 to 1.42)
1.19 (1.07 to 1.31)
1.16 (0.95 to 1.41)
1.06 (0.93 to 1.22)
0.77 (0.38 to 1.56)
0.89 (0.73 to 1.10)
1.06 (0.86 to 1.32)
0.25 0.5 1.0 2.0
Drug Adjusted* odds
ratio (95% CI)
1.18 (1.12 to 1.24)
1.31 (1.15 to 1.48)
1.28 (1.16 to 1.40)
1.29 (1.07 to 1.56)
1.09 (0.96 to 1.24)
1.13 (0.58 to 2.19)
0.86 (0.71 to 1.04)
1.10 (0.89 to 1.34)
Crude odds
ratio (95% CI)
Adjusted* odds
ratio (95% CI)
1357 (36.9)
255 (40.8)
446 (39.9)
116 (40.3)
248 (34.2)
9 (35.3)
107 (27.1)
95 (34.4)
Exposed
group
71 374 (31.5)
Unexposed
group
No with birth
defects (per 1000)
Fig 1 | selective serotonin reuptake inhibitors (ssris) or venlafaxine in early pregnancy and risk of birth defects. *adjusted for 
maternal age, year of birth, birth order, smoking, maternal diabetes, country, and use of other prescribed drugs (antiepileptics 
(atC code n03), anxiolytics and hypnotics (n05b and n05C), and angiotensin converting enzyme inhibitors (C09))
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small numbers of exposed infants, with ambiguous 
findings.16 28 Our study showed no increased risk of 
birth defects with combined use of these drugs.
Our estimated 45% increased prevalence of septal 
defects associated with exposure to fluoxetine is an 
extension of the previous findings from Denmark11 12  and 
Finland.15  In contrast, one study8  reported no associa-
tion between maternal use of fluoxetine and septal 
defects (adjusted odds ratio 1.0, 95% confidence interval 
0.5 to 2.2), but given the lack of precision, those esti-
mates may well have been in line with our findings. In 
our data, exposure to paroxetine was associated with a 
nearly 40% increased prevalence of septal defects, 
which contrasts with previous findings from Denmark,11  12 
Finland,15  and the USA,8  but is in accordance with find-
ings from the Netherlands (adjusted odds ratio 1.6, 95% 
confidence interval 0.4 to 5.6).29  However, the estimated 
effect of sertraline on septal defects in our data does not 
support previous findings from Denmark11 12  and the 
USA,8  reporting a twofold to threefold increased preva-
lence of septal defects in offspring exposed to sertraline. 
We found exposure to all types of SSRI to be associated 
with an increased prevalence of right ventricular out-
flow tract obstructions, which is an extension of the pre-
viously reported findings from Finland15  and consistent 
with findings from earlier studies from the USA.8 9  How-
ever, two recent cohort studies from the USA and the UK, 
respectively, suggested no substantial increase in the 
risk of cardiac birth defects associated with use of anti-
depressants during the first trimester.30  31 These findings 
are in accordance with our estimates when controlling 
for confounding by a sibling controlled design.
When we examined other specific birth defects 
reported in previous studies, we did not find an 
increased prevalence of hypospadias, limb reductions, 
gastroschisis, cystic kidneys, or craniosynostosis. One 
study8  reported a fivefold increased prevalence of 
omphalocele associated with sertraline. We found a 
Any cardiac defects 
 
 
 
 
 
 
Situs anomalies and looping defects 
 
Conotruncal and major arch anomalies 
 
 
 
 
 
Atrial and ventricular septal defects 
 
 
 
 
 
 
Atrioventricular septal defects 
 
 
Right ventricular outflow tract obstructions 
 
 
 
 
Le ventricular outflow tract obstructions
1.15 (1.05 to 1.26)
1.34 (1.10 to 1.63)
1.15 (0.98 to 1.34)
1.30 (0.96 to 1.75)
1.13 (0.93 to 1.38)
0.83 (0.60 to 1.16)
1.14 (0.82 to 1.57)
1.00 (0.52 to 1.90)
1.81 (0.80 to 4.11)
0.95 (0.67 to 1.35)
0.68 (0.26 to 1.83)
0.75 (0.37 to 1.51)
2.27 (1.01 to 5.07)
1.02 (0.48 to 2.15)
1.43 (0.59 to 3.47)
1.17 (1.05 to 1.31)
1.45 (1.15 to 1.84)
1.17 (0.97 to 1.42)
1.37 (0.96 to 1.95)
1.05 (0.82 to 1.35)
0.82 (0.54 to 1.25)
1.10 (0.73 to 1.64)
1.22 (0.77 to 1.91)
1.14 (0.51 to 2.56)
1.81 (0.80 to 4.06)
1.48 (1.15 to 1.89)
1.95 (1.17 to 3.25)
1.65 (1.10 to 2.48)
2.54 (1.31 to 4.90)
1.40 (0.81 to 2.42)
1.09 (0.80 to 1.49)
0.74 (0.31 to 1.77)
1.56 (0.99 to 2.46)
0.82 (0.37 to 1.84)
0.25 0.5 1.0 2.0 3.0 5.0
Type of birth defect Adjusted* odds
ratio (95% CI)
1.30 (1.20 to 1.42)
1.45 (1.19 to 1.75)
1.34 (1.15 to 1.55)
1.57 (1.20 to 2.06)
1.28 (1.06 to 1.55)
0.99 (0.74 to 1.32)
1.23 (0.90 to 1.68)
1.05 (0.58 to 1.91)
2.20 (1.04 to 4.62)
1.08 (0.79 to 1.49)
0.98 (0.44 to 2.18)
0.73 (0.36 to 1.46)
2.13 (0.95 to 4.75)
1.27 (0.66 to 2.44)
1.81 (0.86 to 3.80)
1.33 (1.20 to 1.47)
1.54 (1.22 to 1.94)
1.38 (1.15 to 1.66)
1.67 (1.21 to 2.31)
1.25 (0.99 to 1.59)
0.92 (0.63 to 1.33)
1.17 (0.79 to 1.74)
1.26 (0.83 to 1.93)
1.13 (0.51 to 2.53)
1.75 (0.78 to 3.91)
1.66 (1.32 to 2.10)
2.01 (1.21 to 3.35)
1.95 (1.32 to 2.87)
2.92 (1.57 to 5.43)
1.74 (1.04 to 2.89)
1.14 (0.86 to 1.52)
0.84 (0.38 to 1.87)
1.64 (1.07 to 2.52)
0.72 (0.32 to 1.61)
Crude odds
ratio (95% CI)
Adjusted* odds
ratio (95% CI)
564 (15.3)
106 (17.0)
176 (15.7)
53 (18.4)
109 (15.0)
46 (11.7)
40 (14.5)
11 (0.4)
7 (0.6)
39 (1.1)
6 (1.0)
8 (0.7)
6 (2.1)
9 (1.2)
7 (1.8)
376 (10.2)
74 (11.8)
119 (10.6)
37 (12.9)
70 (9.7)
28 (7.1)
25 (9.1)
22 (0.6)
6 (0.5)
6 (0.8)
73 (2.0)
15 (2.4)
26 (2.3)
10 (3.5)
15 (2.1)
48 (1.3)
6 (1.0)
21 (1.9)
6 (0.8)
Exposed
group
Any SSRI
Fluoxetine
Citalopram
Paroxetine
Sertraline
Escitalopram
Venlafaxine
Any SSRI
Citalopram
Any SSRI
Fluoxetine
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Paroxetine
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Any SSRI
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Unexposed
group
No with birth
defects (per 1000)
Fig 2 | selective serotonin reuptake inhibitors (ssris) or venlafaxine in early pregnancy and risk of cardiac birth defects. *adjusted for maternal age, year 
of birth, birth order, smoking, maternal diabetes, country, and use of other prescribed drugs (antiepileptics (atC code n03), anxiolytics and hypnotics 
(n05b and n05C), and angiotensin converting enzyme inhibitors (C09))
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twofold increased prevalence of omphalocele in infants 
exposed to SSRIs, but this estimate was based on only 
10 cases. In our data, exposure to sertraline was associ-
ated with a 2.5-fold increased prevalence of anal atre-
sia, corroborating but lower than the 3-4-fold increased 
odds previously estimated.8 With a prevalence of 0.5 per 
1000 in SSRI exposed infants, the estimated absolute 
increase of anal atresia was low in our study.
Contrary to our results, a recent case-control study 
found positive associations between prenatal exposure 
to venlafaxine and various birth defects, including car-
diac defects.21 The findings may, however, have been 
complicated by methodological limitations, including 
the small numbers included and a study design suscep-
tible to recall bias.
Mechanism
Biological mechanisms remain unknown for most 
drug-defect associations, but a growing body of evidence 
from animal studies has suggested that the neurotrans-
mitter serotonin is important as a signaling molecule in a 
variety of cells and tissues during embryogenesis, includ-
ing heart development.32  Disruption of the serotonin sig-
naling caused by exposure to SSRIs may thus result in 
disturbances of cardiac development, providing a bio-
logically plausible explanation for the increased risk of 
cardiac birth defects.32-34
strengths and limitations of this study
Our study was based on prospectively collected data 
from five Nordic countries, and the large numbers 
allowed us to study individual SSRIs and specific birth 
defects with independent ascertainment of exposure 
and outcome up to 1 year of age without any risk of recall 
bias. None the less, non-adherence to the dispensed 
antidepressants may have yielded misclassification of 
exposure and thus biased the relative estimates towards 
the null. However, previous Nordic studies comparing 
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Clubfoot
Limb reduction
Craniosynostosis
Omphalocele
Gastroschisis
Cystic kidneys
1.43 (0.88 to 2.32)
1.45 (0.64 to 3.25)
2.47 (1.09 to 5.57)
0.99 (0.79 to 1.25)
1.39 (0.87 to 2.22)
1.27 (0.89 to 1.82)
0.81 (0.48 to 1.38)
1.13 (0.54 to 2.38)
1.34 (1.05 to 1.71)
1.08 (0.58 to 2.02)
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0.99 (0.47 to 2.10)
1.30 (0.58 to 2.93)
2.11 (1.01 to 4.39)
1.65 (0.87 to 3.15)
1.15 (0.68 to 1.94)
0.25 0.5 1.0 2.0 3.0 5.0
Type of birth defect Adjusted* odds
ratio (95% CI)
1.50 (0.95 to 2.37)
1.56 (0.70 to 3.48)
2.81 (1.33 to 5.92)
1.08 (0.86 to 1.34)
1.44 (0.91 to 2.30)
1.39 (0.97 to 1.98)
1.04 (0.62 to 1.72)
1.27 (0.60 to 2.67)
1.50 (1.19 to 1.88)
1.37 (0.78 to 2.42)
1.72 (1.18 to 2.52)
2.07 (1.35 to 3.19)
1.02 (0.63 to 1.64)
1.18 (0.53 to 2.63)
1.17 (0.78 to 1.77)
1.34 (0.67 to 2.68)
1.81 (0.86 to 3.81)
2.28 (1.21 to 4.29)
1.64 (0.90 to 2.99)
1.11 (0.67 to 1.85)
Crude odds
ratio (95% CI)
Adjusted* odds
ratio (95% CI)
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1031 (0.5)
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270 (0.1)
413 (0.2)
834 (0.4)
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Fig 3 | selective serotonin reuptake inhibitors (ssris) or venlafaxine in early pregnancy and risk of non-cardiac birth 
defects. *adjusted for maternal age, year of birth, birth order, smoking, maternal diabetes, and country, and use of other 
prescribed drugs (antiepileptics (atC code n03), anxiolytics and hypnotics (n05b and n05C), and angiotensin converting 
enzyme inhibitors (C09))
table 3 | selective serotonin reuptake inhibitors or venlafaxine in early pregnancy and birth defects. Odds ratios in unmatched and sibling controlled 
analyses
type of birth defect
Full cohort analyses sibling controlled analyses
Crude odds ratio (95% Ci) 
(n=2 303 647)
adjusted* odds ratio  
(95% Ci) (n=2 145 050)
no of 
families
no of 
infants
no 
exposed
no with birth 
defects
Crude odds ratio 
(95% Ci)
adjusted* odds 
ratio (95% Ci)
Any 1.18 (1.12 to 1.24) 1.13 (1.05 to 1.20) 895 2288 980 923 1.04 (0.91 to 1.19) 1.06 (0.91 to 1.24)
Any cardiac 1.30 (1.20 to 1.42) 1.15 (1.05 to 1.26) 378 991 422 386 0.94 (0.76 to 1.16) 0.92 (0.72 to 1.17)
Right ventricular outflow tract 
obstruction
1.66 (1.32 to 2.10) 1.48 (1.15 to 1.89) 42 115 48 42 0.96 (0.51 to 1.81) 0.56 (0.21 to 1.49)
*Adjusted for maternal age, year of birth, birth order, smoking, maternal diabetes, country, and use of other prescribed drugs (antiepileptics (ATC code N03), anxiolytics and hypnotics (N05B and 
N05C), and angiotensin converting enzyme inhibitors (C09))
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data on use of SSRIs from prescription databases with 
self reported SSRI use in pregnant women indicate the 
prescription data to be quite accurate and reliable for 
regular use of drugs such as antidepressants.35-37
Although we had data on several important con-
founders, including maternal age, diabetes, use of 
other potentially teratogenic drugs, and self reported 
smoking, residual confounding cannot be ruled out. By 
using dispensed drugs as a proxy for diabetes we may 
have missed those women with untreated diabetes type 2. 
A Danish cross sectional study based on a population 
survey found that women with an unhealthy lifestyle 
were about 1.5-fold more likely to be current users of 
SSRIs than those with a healthy lifestyle.38 We were 
unable to include information on maternal use of alco-
hol or other lifestyle factors in our study. These factors 
may, however, be correlated with smoking. Thus adjust-
ing for smoking may at least partly have controlled for 
some of the effect. Still, we find it likely that our esti-
mates would have been even closer to 1.0 if we had been 
able to better control for lifestyle factors. This is further 
corroborated by our findings in the sibling controlled 
design. To use a sibling design when both exposure and 
outcome are rare, a large study population is required. 
Even though our study included 2.3 million births, the 
number in the sibling cohort was moderate. The sibling 
design has the advantage of controlling for familial fac-
tors that may be difficult to measure and control for 
in  more conventional analyses. But sibling analyses 
reduce the size of the study population, since only sib-
ling pairs discordant for both exposure and outcome 
are informative and contribute to the effect estimate. 
These births may represent a selected part of the popu-
lation. Moreover, the sibling analysis has lower statisti-
cal power than the conventional cohort study design. 
Yet the upper limits of the confidence intervals were 
similar in the sibling analyses and the covariate 
adjusted cohort analyses. A possible weakness of the 
sibling design could be that use of SSRIs in a later preg-
nancy is not independent of the outcome of a first 
exposed pregnancy. However, in this study the order of 
exposure and outcome between discordant siblings did 
not influence the level of the odds ratios, which would 
suggest no such bias.
We tested several associations, but all the analyses 
were based on a priori stated hypotheses, which were 
built on previously published findings. As the number 
of tests in a study increases, the probability that one of 
them will be falsely positive also increases. We did not, 
however, adjust for multiple testing as this may increase 
the risk of type 2 errors.39 Considering lower statistical 
precision in the sibling controlled analyses, we focused 
on the major outcomes in these analyses, such as any 
birth defect, any cardiac defect, and right ventricular 
outflow tract obstruction defects.
Disentangling the potential teratogenicity of SSRIs 
from a potential effect of the underlying depression 
remains a challenge. We lacked information on severity 
of depression. We presumed, however, that women who 
had a previous hospital admission for a psychiatric dis-
order had more severe depression than women with no 
such admission. Restricting the analyses to women 
without previous hospital contacts for psychiatric dis-
orders did not substantially change our relative esti-
mates. Yet severity of the underlying illness may still 
vary substantially within this group of women.
We used population based data on live births, but we 
lacked information about prenatal diagnosis resulting 
in termination of pregnancy, miscarriages, or stillbirths 
caused by birth defects. If use of SSRIs is related to any 
of these outcomes, selection bias could be present. This 
may have led us to underestimate the association 
between use of SSRIs and birth defects. However, in an 
earlier study based on the same registers, no significant 
associations were found between use of SSRIs during 
pregnancy and risk of stillbirth or infant mortality.26  In 
addition there seems to be no association between use 
of antidepressants and late termination of pregnancy.40 
Data on birth defects were obtained from medical regis-
ters, and previous validation studies suggest high valid-
ity of these diagnoses, with misclassification rates of 
12% for both congenital malformations overall and car-
diac defects.41 42  We cannot, however, rule out that 
increased awareness of the potential for cardiac defects 
in infants exposed to SSRIs prenatally may have intro-
duced surveillance bias and thereby inflated our rela-
tive estimates. Such bias would particularly concern 
less serious cardiac defects, such as ventricular septal 
defects, which often remain undiagnosed in infancy. 
We would, however, expect such differential misclassi-
fication to be of similar magnitude between the differ-
ent types of SSRIs. Furthermore, the fact that we found 
no increased risk of cardiac defects in infants exposed 
to escitalopram argues against substantial surveillance 
bias. The risks of channeling bias are probably small 
considering similar pregnant populations and that pre-
scription patterns of SSRIs to pregnant women differ 
somewhat between the Nordic countries—for example, 
citalopram and fluoxetine are the most prescribed 
SSRIs in Denmark, whereas citalopram and escitalo-
pram are most prescribed in Norway.12 43  We also have to 
consider that women who continue to use antidepres-
sants in pregnancy may differ from those who were 
never prescribed antidepressants and those who 
stopped using antidepressants in pregnancy. Preg-
nancy is a major determinant of cessation of antide-
pressant treatment, which may be explained by 
concerns about potential adverse effects of the drugs.44
Conclusions
Taken together, the results from our covariate adjusted 
analyses and the sibling controlled analyses point 
against a substantial teratogenic effect of SSRIs. Our 
analyses did not suggest a teratogenic effect of venla-
faxine either.
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